COLLPLANT BIOTECHNOLOGIES LT (CLGN)
IL0004960188 - Common Stock
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CLGN Stock Earnings: CollPlant Biotechnologies Beats EPS, Misses Revenue for Q2 2024
CLGN stock results show that CollPlant Biotechnologies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
CLGN Stock Earnings: CollPlant Biotechnologies Beats EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CollPlant Biotechnologies (NASDAQ:CLGN) just reported results for the second qu...
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
/PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants
/PRNewswire/ -- In a significant step in the advancement of regenerative medicine, CollPlant Biotechnologies (Nasdaq: CLGN) and Stratasys Ltd. (Nasdaq: SSYS)...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant Biotechnologies Unveils Inaugural ESG and Sustainability Report
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CLGN Stock Earnings: CollPlant Biotechnologies Meets EPS, Misses Revenue for Q1 2024
CLGN stock results show that CollPlant Biotechnologies met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CLGN Stock Earnings: CollPlant Biotechnologies Misses EPS, Misses Revenue for Q4 2023
CLGN stock results show that CollPlant Biotechnologies missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
CLGN Stock Earnings: CollPlant Biotechnologies Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CollPlant Biotechnologies (NASDAQ:CLGN) just reported results for the fourth qu...
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant Issues Letter to Shareholders
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants
/PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023
Received a $10 million milestone payment in the third quarter from partner, AbbVie Inc., for achieving a major milestone in the second quarter in accordance...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant says patent granted in U.S. for photocurable dermal filler (NASDAQ:CLGN)
CollPlant Biotechnologies has been granted a patent in the U.S. for their dermal filler, expanding their rhCollagen technology into high-value markets.
CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability Initiative
/PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million
Received in July 2023, $10 million from partner, AbbVie, for achieving a major milestone in the second quarter, for the clinical-phase dermal filler product in...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
/PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based...
CollPlant stock gains $10M milestone from AbbVie (NASDAQ:CLGN)
CollPlant Biotech (CLGN) announced Monday the achievement of a $10M milestone payment from AbbVie (ABBV) for developing a dermal and soft tissue filler. Read more here.